Viewing Study NCT06001294

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:47 AM

Ignite Modification Date: 2026-01-05 @ 6:24 PM

Study NCT ID: NCT06001294

Status: UNKNOWN

Last Update Posted: 2023-08-22

First Post: 2023-08-14

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.

Sponsor: Xiangcheng Zhang

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module References Module